Influence of invasive aspergillosis during acute leukaemia treatment on survival after allogeneic stem cell transplantation: a prospective study of the EBMT Infectious Diseases Working Party

被引：3

作者：

Penack, Olaf ^{[1
,45
,46
]}

Tridello, Gloria ^{[2
]}

Salmenniemi, Urpu ^{[3
]}

Martino, Rodrigo ^{[4
]}

Khanna, Nina ^{[5
]}

Perruccio, Katia ^{[6
]}

Fagioli, Franca ^{[7
]}

Richert-Przygonska, Monika ^{[8
]}

Labussiere-Wallet, Helene ^{[9
]}

Maertens, Johan ^{[10
]}

Jubert, Charlotte ^{[11
]}

Aljurf, Mahmoud ^{[12
]}

Pichler, Herbert ^{[13
]}

Krivan, Gergely ^{[14
]}

Kunadt, Desiree ^{[15
]}

Popova, Marina ^{[16
]}

Gabriel, Melissa ^{[17
]}

Calore, Elisabetta ^{[18
]}

Blau, Igor Wolfgang ^{[1
]}

Benedetti, Fabio ^{[19
]}

Itala-Remes, Maija ^{[20
]}

de Kort, Elizabeth ^{[21
]}

Russo, Domenico ^{[22
]}

Faraci, Maura ^{[23
]}

Menard, Anne-Lise ^{[24
]}

von dem Borne, Peter ^{[25
]}

Poire, Xavier ^{[26
]}

Yesilipek, Akif ^{[27
]}

Gozdzik, Jolanta ^{[28
]}

Yegin, Zeynep Arzu ^{[29
]}

Yanez, Lucrecia ^{[30
]}

Facchini, Luca ^{[31
]}

Van Gorkom, Gwendolyn ^{[32
]}

Thurner, Lorenz ^{[33
]}

Kocak, Ulker ^{[34
]}

Sampol, Antonia ^{[35
]}

Zuckerman, Tsila ^{[36
]}

Bierings, Marc ^{[37
]}

Mielke, Stephan ^{[38
]}

Ciceri, Fabio ^{[39
]}

Wendel, Lotus ^{[2
]}

Knelange, Nina ^{[2
]}

Mikulska, Malgorzata ^{[40
,41
]}

Averbuch, Dina ^{[42
]}

Styczynski, Jan ^{[8
]}

de la Camara, Rafael ^{[43
]}

Cesaroaq, Simone ^{[44
]}

机构：

[1] Med Klin m S Hamatol Onkol & Tumorimmunol, Berlin, Germany

[2] EBMT Leiden Study Unit, Leiden, Netherlands

[3] HUCH Comprehens Canc Ctr, Helsinki, Finland

[4] Hosp Sant Creu i Sant Pau, Barcelona, Spain

[5] Univ Basel Hosp, Div Infect Dis, Basel, Switzerland

[6] Santa Maria Della Misericordia Hosp, Pediat Oncol Hematol & Stem Cell Transplantat Prog, Perugia, Italy

[7] Osped Infantile Regina Margher, Turin, Italy

[8] Nicolaus Copernicus Univ Torun, Jurasz Univ Hosp, Dept Pediat Hematol & Oncol, Coll Medicum, Bydgoszcz, Poland

[9] Hosp Civils Lyon, Hop Lyon Sud, Pierre Benite, France

[10] Univ Hosp Gasthuisberg, Leuven, Belgium

[11] CHU Bordeaux Grp Hosp Pellegrin Enfants, Bordeaux, France

[12] King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi Arabia

[13] Med Univ Vienna, St Anna Childrens Hosp, Dept Pediat & Adolescent Med, Vienna, Austria

[14] Cent Hosp Southern Pest, Budapest, Hungary

[15] Tech Univ Dresden, Univ Hosp, Dresden, Germany

[16] Pavlov Univ, RM Gorbacheva Res Inst, St Petersburg, Russia

[17] Childrens Hosp Westmead, Canc Ctr Children, Sydney, Australia

[18] Univ Padua, Azienda Osped, Dept Womens & Childrens Hlth, Pediat Hematol Oncol & Stem Cell Transplant Div, Padua, Italy

[19] Policlin GB Rossi, Verona, Italy

[20] Turku Univ Hosp, Turku, Finland

[21] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[22] Brescia Univ, Unit Blood Dis & Bone Marrow Transplantat, Brescia, Italy

[23] IRCCS Ist G Gaslini, Dept Hematol Oncol, HSCT Unit, Genoa, Italy

[24] Ctr Henri Becquerel, Rouen, France

[25] Leiden Univ Hosp, Leiden, Netherlands

[26] Clin Univ St Luc, Brussels, Belgium

[27] Med Pk Antalya Hosp, Antalya, Turkiye

[28] Jagiellonian Univ Med Collage, Univ Childrens Hosp Krakow, Dept Clin Immunol & Transplantat, Krakow, Poland

[29] Gazi Univ, Fac Med, Ankara, Turkiye

[30] Hosp U Marques de Valdecilla IDIVAL, Santander, Spain

[31] AUSL IRCCS Reggio Emilia, Hematol, Reggio Emilia, Italy

[32] Univ Hosp Maastricht, Maastricht, Netherlands

[33] Univ Saarland, Lorenz Thurner, Homburg, Germany

[34] Gazi Univ, Sch Med, Ankara, Turkiye

[35] Hosp Son Espases, Palma De Mallorca, Balearic Island, Spain

[36] Technion, Rambam Med Ctr, Fac Med, Haifa, Israel

[37] Univ Hosp Children WKZ, Princess Maxima Ctr, Utrecht, Netherlands

[38] Karolinska Univ Hosp, Stockholm, Sweden

[39] Univ V Salute San Raffaele, Milan, Italy

[40] Univ Genoa, Div Infect Dis, Genoa, Italy

[41] Osped Policlin San Martino, Genoa, Italy

[42] Hebrew Univ Jerusalem, Fac Med, Hadassah Med Ctr, Pediat Infect Dis, Jerusalem, Israel

[43] Hosp Princesa, Madrid, Spain

[44] Azienda Osped Univ Integrata, Dept Mother & Child, Pediat Hematol Oncol, Verona, Italy

[45] Charite, Dept Hematol Oncol & Tumorimmunol, Campus Virchow Klinikum, Augustenburger Pl 1, D-13353 Berlin, Germany

[46] Charite Univ Med Berlin, Dept Hematol Oncol & Tumorimmunol, Campus Virchow Clin, Augustenburger Pl 1, D-13353 Berlin, Germany

来源：

ECLINICALMEDICINE | 2024年 / 67卷

关键词：

Invasive; Aspergillosis; Stem cell transplantation; Mortality; SECONDARY ANTIFUNGAL PROPHYLAXIS; HEMATOLOGICAL MALIGNANCIES; NEUTROPENIC PATIENTS; FUNGAL-INFECTION; EXPERIENCE; SOCIETY; IMPACT; BLOOD; HSCT;

D O I：

10.1016/j.eclinm.2023.102393

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background Infections are the main reason for mortality during acute leukaemia treatment and invasive aspergillosis (IA) is a major concern. Allogeneic stem cell transplantation (alloSCT) is a standard therapy and often is the only saving procedure in leukaemia patients. The profound immunodeficiency occurring after alloSCT led to high associated mortality in the past. Therefore, patients with IA were historically considered transplant-ineligible. Recently, there has been improvement of anti-fungal management including novel anti-fungal agents. As a result, more leukaemia patients with IA are undergoing alloSCT. Outcome has not been prospectively assessed. Methods We performed a prospective study in acute leukaemia patients undergoing alloSCT to analyse the impact a prior history of probable or proven IA (pre-SCT IA). The primary endpoint was 1-year non-relapse mortality (NRM). Relapse free survival and overall survival were analysed as secondary endpoints. Findings 1439 patients were included between 2016 and 2021. The incidence of probable or proven pre-SCT IA was (n = 87). The cumulative incidence of 1-year NRM was 17.3% (95% CI 10.2-26.0) and 11.2% (9.6-13.0) for patients and without pre-SCT IA. In multivariate analyses the hazard ratio (HR) for 1-year NRM was 2.1 (1.2-3.6; p = 0.009) patients with pre-SCT IA. One-year relapse-free survival was inferior in patients with pre-SCT IA (59.4% [48.3-68.9] 70.4 [67.9-72.8]; multivariate HR 1.5 [1.1-2.1]; p = 0.02). Consequently, 1-year overall survival was lower in patients with pre-SCT IA: (68.8% [57.8-77.4] vs. 79.0% [76.7-81.1]; multivariate HR 1.7 [1.1-2.5]; p = 0.01). Interpretation Pre-SCT IA remains to be significantly associated with impaired alloSCT outcome. On the other more than two thirds of patients with pre-SCT IA were alive at one year after alloSCT. IA is not anymore an absolute contraindication for alloSCT because the majority of patients with IA who undergo alloSCT benefit from this procedure.

引用

页数：10

共 50 条

[21] Monitoring and management of CMV and EBV after autologous haematopoietic stem cell transplantation for autoimmune diseases: a survey of the EBMT Autoimmune Diseases Working party (ADWP)
Alexander, Tobias
Badoglio, Manuela
Labopin, Myriam
Daikeler, Thomas
Farge, Dominique
Kazmi, Majid
Rovira, Montserrat
Roldan, Elisa
Snowden, John
Raffaella, Greco
BONE MARROW TRANSPLANTATION, 2025, 60 (01) : 110 - 113
[22] Variability of nutritional practices in peritransplant period after allogeneic hematopoietic stem cell transplantation: a survey by the Complications and Quality of Life Working Party of the EBMT
Peric, Zinaida
Botti, Stefano
Stringer, Jacqui
Krawczyk, Joanna
van der Werf, Steffie
van Biezen, Anja
Aljurf, Mahmoud
Murray, John
Liptrott, Sarah
Greenfield, Diana M.
Duarte, Rafael F.
Ruutu, Tapani
Basak, Grzegorz W.
BONE MARROW TRANSPLANTATION, 2018, 53 (08) : 1030 - 1037
[23] Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT
Styczynski, Jan
Tridello, Gloria
Koster, Linda
Knelange, Nina
Wendel, Lotus
van Biezen, Anja
van der Werf, Steffie
Mikulska, Malgorzata
Gil, Lidia
Cordonnier, Catherine
Ljungman, Per
Averbuch, Diana
Cesaro, Simone
Baldomero, Helen
Chabannon, Christian
Corbacioglu, Selim
Dolstra, Harry
Glass, Bertram
Greco, Raffaella
Kroeger, Nicolaus
de Latour, Regis Peffault
Mohty, Mohamad
Neven, Benedicte
Peric, Zinaida
Snowden, John A.
Sureda, Anna
Yakoub-Agha, Ibrahim
de la Camara, Rafael
BONE MARROW TRANSPLANTATION, 2023, 58 (08) : 881 - 892
[24] CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT
Schmidt-Hieber, Martin
Labopin, Myriam
Beelen, Dietrich
Volin, Liisa
Ehninger, Gerhard
Finke, Juergen
Socie, Gerard
Schwerdtfeger, Rainer
Kroeger, Nicolaus
Ganser, Arnold
Niederwieser, Dietger
Polge, Emmanuelle
Blau, Igor W.
Mohty, Mohamad
BLOOD, 2013, 122 (19) : 3359 - 3364
[25] Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT
Heidenreich, Silke
Ziagkos, Dimitris
de Wreede, Liesbeth C.
van Biezen, Anja
Finke, Juergen
Platzbecker, Uwe
Niederwieser, Dietger
Einsele, Hermann
Bethge, Wolfgang
Schleuning, Michael
Beelen, Dietrich W.
Tischer, Johanna
Nagler, Arnon
Glass, Bertram
Maertens, Johan
Yanez, Lucrecia
Beguin, Yves
Sill, Heinz
Scheid, Christof
Stelljes, Matthias
Ganser, Arnold
Zachee, Pierre
Selleslag, Dominik
de Witte, Theo
Robin, Marie
Kroeger, Nicolaus
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (01) : 44 - 52
[26] Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT
Martinez, Carmen
Boumendil, Ariane
Romejko-Jarosinska, Joanna
Anagnostopoulos, Achilles
Faber, Edgar
Poire, Xavier
Yakoub-Agha, Ibrahim
Akhtar, Saad
Gurman, Gunhan
Pavone, Vincenzo
Halaburda, Kazimierz
Sousa, Aida Botelho
Ghesquieres, Herve
Finel, Herve
Khvedelidze, Irma
Montoto, Silvia
Sureda, Anna
LEUKEMIA & LYMPHOMA, 2020, 61 (12) : 2915 - 2922
[27] Incidence and Risk Factors for Acute Kidney Injury after Allogeneic Stem Cell Transplantation: A Prospective Study
Andronesi, Andreea
Sorohan, Bogdan
Burcea, Andreea
Lipan, Lavinia
Stanescu, Cristina
Craciun, Oana
Stefan, Laura
Ranete, Adela
Varady, Zsofia
Ungureanu, Oana
Lupusoru, Gabriela
Agrigoroaei, Gabriela
Andronesi, Danut
Iliuta, Luminita
Obrisca, Bogdan
Tanase, Alina
BIOMEDICINES, 2022, 10 (02)
[28] Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT
Robin, Marie
Iacobelli, Simona
Koster, Linda
Passweg, Jakob
Avenoso, Daniele
Wilson, Keith M. O.
Salmenniemi, Urpu
Dreger, Peter
von dem Borne, Peter
Snowden, John A.
Robinson, Stephen
Finazzi, Maria Chiara
Schroeder, Thomas
Collin, Matthew
Eder, Matthias
Forcade, Edouard
Loschi, Michael
Bramanti, Stefania
Antonio Perez-Simon, Jose
Czerw, Tomasz
Polverelli, Nicola
Drozd-Sokolowska, Joanna
Raj, Kavita
Carlos Hernandez-Boluda, Juan
McLornan, Donal P.
BONE MARROW TRANSPLANTATION, 2024, 59 (07) : 928 - 935
[29] Anti-Thymocyte Globulin Improves Survival Free From Relapse and Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Philadelphia-Negative Acute Lymphoblastic Leukemia: An Analysis by the Acute Leukemia Working Party of the EBMT
Czerw, Tomasz
Labopin, Myriam
Giebel, Sebastian
Socie, Gerard
Volin, Liisa
Fegueux, Nathalie
Masszi, Tamas
Blaise, Didier
Chaganti, Sridhar
Cornelissen, Jan J.
Passweg, Jakob
Maertens, Johan
Itala-Remes, Maija
Wu, Depei
Mohty, Mohamad
Nagler, Arnon
CANCER, 2018, 124 (12) : 2523 - 2533
[30] Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT
Spyridonidis, A.
Labopin, M.
Schmid, C.
Volin, L.
Yakoub-Agha, I.
Stadler, M.
Milpied, N.
Socie, G.
Browne, P.
Lenhoff, S.
Sanz, M. A.
Aljurf, M.
Mohty, M.
Rocha, V.
LEUKEMIA, 2012, 26 (06) : 1211 - 1217

← 1 2 3 4 5 →